SAR-448501

N/A

Report date: 2026/03/21 20:00:21

First In Class

Base Information

Drug NameSAR-448501

Drug Alias NameDR-0201SAR-448501

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionPhagocytes stimulantsT lymphocytes stimulantsAnti-CD20

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLupus Erythematosus, SystemicArthritis, RheumatoidLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBosnia and HerzegovinaSingaporeTaiwan +[8]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesDren Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesSanofi Dren Bio Inc

Inactive CompaniesN/A

Active IndicationsLupus Erythematosus, SystemicArthritis, RheumatoidLymphoma, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A